secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K
Filed at:   2026-08-10T11:57:19+00:00
Accession:  0001193125-26-341293
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics reports positive Phase 2 SANRECO topline: 88% vs 19% responder rate
--------------------------------------------------------------------------------

- Primary endpoint met: 88% clinical responders on divesiran vs 19% placebo (p<0.0001); placebo-adjusted 69%.
- Both dose groups strong: 93.8% response at Q6W, 81.3% at Q12W in 48 phlebotomy-dependent PV patients.
- Phlebotomy rate cut to 0.2 vs 2.1 per patient (p<0.0001); hematocrit control and MPN-SAF TSS improved.
- Well tolerated, no new safety findings; two grade 1 anemia cases. Phase 3 Q12W vs placebo expected 1H'27.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312526341293/0001193125-26-341293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312526341293/d12947d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-341293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer